BioStock: Ultimovacs’ clinical data presented at ASCO
This year’s virtual ASCO conference featured Ultimovacs’ recently released phase I data showing that cancer vaccine UV1 boosts the effects of checkpoint inhibitor pembrolizumab leading to a 60 per cent objective response rate in malignant melanoma patients. BioStock was able to get in touch with the trial’s lead investigator Yousef Zakharia, MD, to learn more about why these data are so important.
Read the interview with Yousef Zakharia at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.